Bovie Medical Corporation (NASDAQ:BVX) has earned an average broker rating score of 1.33 (Strong Buy) from the three analysts that cover the company, Zacks Investment Research reports. One investment analyst has rated the stock with a buy recommendation and two have given a strong buy recommendation to the company.

Brokerages have set a one year consensus target price of $9.17 for the company and are forecasting that the company will post ($0.09) EPS for the current quarter, according to Zacks. Zacks has also given Bovie Medical an industry rank of 106 out of 257 based on the ratings given to related companies.

Separately, Dougherty & Co restated a “buy” rating and set a $11.00 price objective on shares of Bovie Medical in a research report on Friday, September 14th.

Shares of Bovie Medical stock traded down $0.43 during trading on Friday, reaching $7.07. 198,518 shares of the stock traded hands, compared to its average volume of 131,153. Bovie Medical has a 52-week low of $2.28 and a 52-week high of $7.62.

Bovie Medical Company Profile

Bovie Medical Corporation, a medical device company, develops, manufactures, and markets electrosurgical devices and technologies, and related medical products used in doctor's offices, surgery centers, and hospitals worldwide. The company provides electrosurgical products, including desiccators, generators, electrodes, electrosurgical pencils, and various ancillary disposable products used during surgical procedures in gynecology, urology, plastic surgery, dermatology, veterinary, and other surgical markets for the cutting and coagulation of tissue.

Read More: Diversification

Get a free copy of the Zacks research report on Bovie Medical (BVX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Bovie Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bovie Medical and related companies with MarketBeat.com's FREE daily email newsletter.